Streetbeat News

GRTX

Galera Therapeutics Inc

Employees

41

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.

Open

0.04

Mkt cap

2.1M

Volume

7.4K

High

0.04

P/E Ratio

-0.07

52-wk high

0.29

Low

0.04

Div yield

N/A

52-wk low

0.04

Galera Therapeutics has received a notice of allowance for its U.S. patent application 17/378,852, titled 'Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability,' aimed at reducing oral mucositis in head-and-neck cancer patients from chemoradiation.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 7:58 pm

In Friday's after-market session, several healthcare stocks showed notable movements. Mobile-health Network (MNDR) led the gainers with a 15.0% increase, while Vaxxinity (VAXX) experienced the largest drop among the losers, declining by 10.7%. Other notable movers included Galera Therapeutics (GRTX) and Titan Pharma (TTNP).

Portfolio Pulse from Benzinga Insights

April 19, 2024 | 8:31 pm

Healthcare stocks experienced significant movements in Wednesday's intraday session. INVO Bioscience led the gainers with a 275% increase following its Q4 earnings report, while Dare Bioscience topped the losers, dropping 40.7%. Other notable movers included Vanda Pharma, Galera Therapeutics, and SINTX Techs on the gainers' side, and Longeveron, Sage Therapeutics, and China SXT Pharmaceuticals among the losers.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 4:31 pm

In Wednesday's pre-market session, health care stocks saw significant movements. INVO Bioscience led the gainers with a 93.4% increase following their Q4 earnings release. Other notable gainers include Clene, Galera Therapeutics, Vanda Pharma, Chromocell Therapeutics, and BIMI Intl Medical. On the losing side, Sage Therapeutics saw the largest drop of 19.4%, followed by declines in Ontrak, China SXT Pharmaceuticals, Dynatronics, Etao International Co, and Precision BioSciences.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 12:08 pm

Doma Holdings Inc. shares surged 34.1% in pre-market trading after announcing a merger with TRG to go private at $6.29 per share. Other stocks showed significant movement in pre-market trading, with Vast Renewables Limited leading the gainers with a 213.9% increase, and Mountain Crest Acquisition Corp. IV leading the losers with a 58.7% decrease. The movements were influenced by various factors including earnings reports, strategic partnerships, and public offerings.

Portfolio Pulse from Avi Kapoor

April 01, 2024 | 12:08 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. Galera Therapeutics (GRTX) led the gainers with a 62.8% increase, attributed to its Q4 earnings report. Other notable gainers include Sunshine Biopharma (SBFM), Qilian Intl Hldg Gr (QLI), Xilio Therapeutics (XLO), Innate Pharma (IPHA), and China Pharma Holdings (CPHI). On the losing side, ENDRA Life Sciences (NDRA) saw the largest drop of 29.3%, also following its Q4 earnings. Other decliners were SINTX Techs (SINT), Fractyl Health (GUTS), Vivos Therapeutics (VVOS), Avalo Therapeutics (AVTX), and Applied Therapeutics (APLT).

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:08 pm

In Friday's after-market session, several healthcare stocks showed significant movement. Notably, Qilian Intl Hldg Gr, Sunshine Biopharma, and Galera Therapeutics were among the top gainers, with Qilian Intl leading with a 63.8% increase. On the downside, Vivos Therapeutics, ENDRA Life Sciences, and Applied Therapeutics experienced notable declines, with Vivos Therapeutics dropping 22.4%. The movements were largely attributed to the release of Q4 earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

March 29, 2024 | 8:30 pm

Galera Therapeutics (NASDAQ:GRTX) reported Q4 earnings, beating estimates with an EPS of $-0.1 against an expected $-0.35. However, revenue remained unchanged from the previous year. The company had previously seen a 3.0% stock price increase following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 11:45 am

As of December 31, 2023, Galera Therapeutics, Inc. (GRTX) reported having $18.3 million in cash and cash equivalents, which is anticipated to fund operations into the second quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:17 am

Galera Therapeutics (NASDAQ:GRTX) reported a Q4 EPS loss of $(0.10), surpassing the analyst consensus estimate of $(0.35) by 71.43%. This represents an 82.76% improvement over the $(0.58) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 11:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.